iGrow Clinical Study Recognized as Best Overall Experimental and Translational Research in Low-Level Laser Therapy
The clinical study of the iGrow® Hair Growth System titled “ The Growth of Human Scalp Hair Mediated by Visible Red Light Laser and LED Sources in Males ” was recently recognized at the 33rd Annual Conference of the American Society for Laser Medicine & Surgery, Inc. (ASLMS). The study, which was led by Raymond J. Lanzafame, M.D., M.B.A., F.A.C.S., a board-certified surgeon and expert in laser applications and laser research, was awarded the Best Overall Experimental and Translational Research Award. The study has also been published in the October 2013 issue of Lasers in Surgery and Medicine. The ASLMS annual conference unites a multidisciplinary group of scientists, clinicians, residents, students, healthcare professionals, and industry representatives to address state-of-the-art clinical and research applications of laser technologies and investigate the future of patient care.
The iGrow Hair Growth System, developed by Apira Science, Inc., a pioneer of low-level laser therapy (LLLT) for over a decade, is a highly effective, hands-free LLLT hair growth device cleared by the FDA for use at home. Its patented red light technology treats affected areas of the scalp by energizing unhealthy follicle cells and promoting hair growth. It is indicated to promote hair growth in males with androgenetic alopecia who have Norwood Hamilton Classifications of IIa to V.
The award-winning clinical study was conducted using a double-blind, randomized controlled trial to define the safety and physiologic effects of LLLT, delivered by an iGrow Hair Growth System, on male scalp hair follicles and surrounding tissue. Participants who submitted to iGrow treatments every other day at home saw a 35 percent increase in hair growth over a 16-week period with no side effects.
“The clinical study was conducted on 44 men ranging in age from 18 to 48, all afflicted with varying levels of androgenetic alopecia—male pattern baldness,” said Dr. Lanzafame. “The results of the study showed the iGrow Hair Growth System to be an effective and safe method for increasing scalp hair counts in men, as compared to those who used an identical-appearing placebo device.” The ASLMS awarded the iGrow study one of the highest honors at its annual conference, placing it among four award recipients honored for exceptional research or other contributions in the laser technology field. ASLMS accepted 305 abstracts for presentation at the 2013 Annual Conference. Papers receiving awards were selected from 20 nominees for the prestigious conference awards.
“Through groundbreaking research like that conducted by Dr. Lanzafame, we’re able to show unequivocally that at-home use of LLLT can reverse hair loss in men suffering from androgenetic alopecia,” said Jeff Braile, President of Medical Products at Apira Science, Inc. “We’re already building upon this research with a second clinical trial that was recently completed to measure the effectiveness of the iGrow in treating women’s hair loss. We are confident that this trial will deliver similar positive results. This recognition by the ASLMS further validates the success of the iGrow Hair Growth System for men as an effective and safe alternative to more cumbersome and costly traditional hair-loss treatments.”
For more information on the iGrow Hair Growth System, visit www.igrowlaser.com.